EN
Acadia Healthcare Stock In Focus After Earnings Beat And 2026 Guidance Raise
- Acadia Healthcare Company reported third quarter 2026 revenue of US$895.31 million and raised full year 2026 revenue guidance to a range of US$3.44 billion to US$3.46 billion, alongside higher adjusted earnings than analysts expected.
- Behind the headline numbers, the business is leaning on acute volume growth, added licensed beds and lower capital spending, which together free up more cash for debt reduction and future behavioral health capacity.
- This raises the question of how Acadia Healthcare's updated 2026 guidance and facility expansion could influence the investment narrative from here.
Acadia Healthcare Company Investment Narrative Recap
To own Acadia Healthcare Company, you need to believe that demand for behavioral health care supports its expanding bed base and that new facilities move from startup losses to meaningful EBITDA contribution. The updated 2026 guidance and Q3 beat point to operational momentum, but reported net income and EPS for both the quarter and nine months show that profitability remains tight.
The most important short-term swing factor is how efficiently Acadia fills new beds while managing payer mix and denials. The biggest risk is that legal, regulatory, and liability costs or tougher Medicaid policies eat into margins just as capital spending eases and investors look for clearer earnings traction.
The clearest recent marker for that tension is the raised full-year 2026 revenue outlook to US$3.44 billion to US$3.46 billion. That sits alongside guidance for about US$60 million of incremental adjusted EBITDA in 2027 from facilities opened since 2023, which ties the story directly to execution on bed ramp-up and occupancy.
For investors, the takeaway is straightforward: the guidance increase and new Jacksonville acute facility highlight the operational opportunity, while the nine-month earnings profile and ongoing payer and legal headwinds keep the risk side visible. Any change in how quickly those new facilities contribute EBITDA is likely to shape how the Acadia Healthcare equity story is viewed.
Acadia Healthcare Company is tied to analyst expectations that revenues reach US$4.0 billion and earnings total US$229.5 million by 2029, which rests on forecast revenue growth of 5.9% per year and an earnings swing of roughly US$1.33 billion from a loss of US$1.1 billion today to US$229.5 million of profit.
Uncover why Acadia Healthcare Company's fair value indicates a 3% potential downside to its current price, which leaves little room for error.
Exploring Other Perspectives
One optimistic angle on Acadia Healthcare Company focuses on free cash flow and debt paydown. The most bullish analysts were modeling about US$4.1b of revenue and roughly US$402.9 million of earnings by 2029 before this guidance hike. If you find that appealing, treat this new update as a prompt to compare several competing stories, not a verdict.
Explore 3 other Acadia Healthcare Company fair value estimates, including one that suggests a potential upside of up to 346% from the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Acadia Healthcare Company research is our analysis highlighting 3 key rewards that could impact your investment decision.
- See our latest analysis for Acadia Healthcare Company. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Acadia Healthcare Company's overall financial health at a glance.
Looking for more investment ideas beyond Acadia Healthcare Company?
Once you have a view on Acadia Healthcare Company, it can help to compare it with other opportunities that fit different risk and income preferences using the Simply Wall St Screener.
- If you want resilient balance sheets and fewer financial surprises, scan a 32 resilient stocks with low risk scores that may better match a more cautious approach.
- For investors focused on value and quality together, review a 42 high quality undervalued stocks that combine healthier cash flows with sturdier finances.
- If you are hunting for lesser known stories with solid fundamentals, check out a 21 high quality undiscovered gems that might not yet be widely followed by the market.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com